S100A9 and plasma cell myeloma: In conclusion, myeloid-derived S100A9 can enhance TNFSF13B/TNFRSF13B expression on myeloma cells, stimulating both canonical and non-canonical NF-κB pathways and thereby fuels tumor cell proliferation.